A
Adedigbo A. Fasanmade
Researcher at University of Medicine and Dentistry of New Jersey
Publications - 6
Citations - 1126
Adedigbo A. Fasanmade is an academic researcher from University of Medicine and Dentistry of New Jersey. The author has contributed to research in topics: Infliximab & Rheumatoid arthritis. The author has an hindex of 6, co-authored 6 publications receiving 1074 citations.
Papers
More filters
Journal ArticleDOI
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.
E. William St. Clair,Carrie Wagner,Adedigbo A. Fasanmade,Benjamin Wang,Thomas F. Schaible,Arthur Kavanaugh,Edward C. Keystone +6 more
TL;DR: It is suggested that some patients with RA may benefit from infliximab given at higher doses than 3 mg/kg or more frequently than every 8 weeks.
Journal ArticleDOI
A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritis
Nicolino Ruperto,Daniel J. Lovell,Ruben Cuttica,Nick Wilkinson,Patricia Woo,Graciela Espada,Carine Wouters,Earl D. Silverman,Zsolt Balogh,Michael Henrickson,Maria Teresa Apaz,Eileen Baildam,Anders Fasth,Valeria Gerloni,Pekka Lahdenne,AM Prieur,Angelo Ravelli,Rotraud K. Saurenmann,M.L. Gamir,Nico M Wulffraat,László Maródi,Ross E. Petty,Rik Joos,Francesco Zulian,Deborah McCurdy,Barry L. Myones,K. Nagy,Peter Reuman,Ilona S. Szer,Suzanne Travers,A. Beutler,Greg Keenan,Jason Clark,Sudha Visvanathan,Adedigbo A. Fasanmade,Aparna Raychaudhuri,Alan M. Mendelsohn,Alberto Martini,Edward H. Giannini +38 more
TL;DR: Safety data indicated that the 6-mg/kg dose may provide a more favorable risk/benefit profile for infliximab in the treatment of juvenile rheumatoid arthritis, and achievement of the primary efficacy end point at 3 months did not differ significantly between inflIXimab-treated and placebo-treated patients.
Journal ArticleDOI
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
Alice B. Gottlieb,Salman Masuda,Rallapalli Ramamurthi,Ahsan A. Abdulghani,Pat Romano,Umesh Chaudhari,Lisa T. Dooley,Adedigbo A. Fasanmade,Carrie L. Wagner +8 more
TL;DR: The clinical and immunohistologic data demonstrate a pivotal role for tumor necrosis factor-alpha in the pathogenesis of psoriasis and support further development of drugs targeting tumor Necrosis Factor-alpha.
Journal ArticleDOI
Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension
Nicolino Ruperto,Daniel J. Lovell,Ruben Cuttica,Patricia Woo,Silvia Meiorin,Carine Wouters,Earl D. Silverman,Zsolt Balogh,Michael Henrickson,Joyce Davidson,Ivan Foeldvari,Lisa Imundo,Gabriele Simonini,Joachim Oppermann,Stephen Xu,Yaung Kaung Shen,Sudha Visvanathan,Adedigbo A. Fasanmade,Alan M. Mendelsohn,Alberto Martini,Alberto Martini,Edward H. Giannini +21 more
TL;DR: In the limited population of JRA patients remaining in the study at 4 years, infliximab was safe and effective but associated with a high patient discontinuation rate.
Journal ArticleDOI
2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension
N Ruperto,Daniel J. Lovell,Ruben Cuttica,P Woo,G Espada,Carine Wouters,Earl D. Silverman,Zsolt Balogh,Michael Henrickson,Joyce Davidson,Ivan Foeldvari,Lisa Imundo,Gabriele Simonini,J Oppermann,YK Shen,Sudha Visvanathan,Adedigbo A. Fasanmade,Alan M. Mendelsohn,Alberto Martini,Edward H. Giannini +19 more
TL;DR: Continuous IFX+MTX administered up to 4 yrs was safe & effective in JRA patients, although accompanied by a high rate of patient discontinuation, which included subjects in remission.